ReviewPharmaceutical nanotechnology2026
Solid Lipid Nanoparticles and Nanostructured Lipid Particles: A Comparative Review on Lipid-based Nanocarriers.
Review in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nanocarrier Systems for Plant-Derived Bioactives: Design, Biosafety, and Translational Challenges.Pharmaceutics · 2026Review
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Beyond Symptom Suppression: The Multitargeted Reversal of Chronic Pain by Maresin1.Drug design, development and therapy · 2026Review
- From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson's Disease Therapies.Biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid-based nanocarriers have emerged as promising vehicles for the delivery of various therapeutic agents, owing to their biocompatibility, stability, and ability to encapsulate both hydrophilic and hydrophobic drugs. Among these lipid-based nanocarriers, Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) have gained significant attention in the field of drug delivery. This comparative review aims to provide a comprehensive analysis of SLNs and NLCs, focusing on their formulation, physicochemical properties, drug-loading capacity, stability, and drug release profiles. The review highlights the differences in preparation techniques, particle size, zeta potential, drug encapsulation efficiency, stability, drug delivery, cosmetic and personal care, and food industry applications between SLN and NLC. Furthermore, the review discusses the toxicity and safety profiles of these nanoparticles, including cytotoxicity, genotoxicity, acute toxicity, and long-term toxicity. Finally, the review identifies the potential applications, limitations, and future research directions of SLN and NLC. In summary, this comparative review provides valuable insights into the formulation, physicochemical properties, drug-loading capacity, stability, and drug release profiles of SLNs and NLCs. By understanding the similarities and differences between these lipid-based nanocarriers, researchers and pharmaceutical scientists can make informed decisions regarding the selection of the most suitable nanocarrier for specific therapeutic applications.
Indexed as
Identifiers
39660518What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.